Chugai Pharma UK - Products

RoActemra Concentrate for Solution for Infusion (tocilizumab)

RoActemra, in combination with methotrexate (MTX), is indicated for 

  • The treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX
  • The treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate
  • The treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX
  • The treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate

(This is a brief indication for use; for details please see SPC.)

Summary of Product Characteristics
Patient Information Leaflet

RoActemra Solution for Injection in Pre-Filled Syringe (tocilizumab)

RoActemra, in combination with methotrexate (MTX), is indicated for:

  • The treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate

(This is a brief indication for use; for details please see SPC.)

Summary of Product Characteristics
Patient Information Leaflet

Adverse events for RoActemra should be reported to Roche Products Ltd. Please contact Roche drug safety centre by emailing [email protected] or calling +44(0) 1707 367554.
As RoActemra is a biological medicine, Healthcare Professionals should report adverse reactions by brand name and batch number. 
 

Granocyte (lenograstim)

Granocyte is indicated in adults, adolescents and children older than 2 years for

  • The reduction in the duration of neutropenia in patients (with non myeloid malignancy) undergoing myeloablative therapy followed by bone marrow transplantation (BMT) in patients considered to be at increased risk of prolonged severe neutropenia
  • The reduction of duration of severe neutropenia and its associated complications in patients undergoing established cytotoxic chemotherapy associated with a significant incidence of febrile neutropenia
  • The mobilisation of peripheral blood progenitor cells (PBPCs), for patients as well as healthy donors

(This is a brief indication for use; for details please see SPC.)

Summary of Product Characteristics
Patient Information Leaflet

Aloxi 250 micrograms solution for injection

Aloxi is indicated in adults for

  • The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy
  • The prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy

Aloxi is indicated in paediatric patients 1 month of age and older for

  • The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy

(This is a brief indication for use; for details please see SPC.)

Summary of Product Characteristics 
Patient Information Leaflet

Aloxi 500 microgrammes soft capsules

Aloxi is indicated in adults for

  • The prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy

(This is a brief indication for use; for details please see SPC.)

Summary of Product Characteristics 
Patient Information Leaflet

Antepsin Oral Suspension (sucralfate)

Indicated for

  • The treatment of duodenal ulcer, gastric ulcer, chronic gastritis, and the prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients.

(This is a brief indication for use; for details please see SPC.)

Summary of Product Characteristics
Patient Information Leaflet

Antepsin Tablets (sucralfate)

Indicated for

  • The treatment of duodenal ulcer, gastric ulcer, chronic gastritis.

(This is a brief indication for use; for details please see SPC.)

Summary of Product Characteristics
Patient Information Leaflet

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Chugai Pharma UK Ltd., on [email protected].